These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 28303277)

  • 1. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.
    Deza G; Bertolín-Colilla M; Pujol RM; Curto-Barredo L; Soto D; García M; Hernández P; Gimeno R; Giménez-Arnau AM
    Acta Derm Venereol; 2017 Jun; 97(6):698-704. PubMed ID: 28303277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
    Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
    Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved FcεRI-Mediated CD203c Basophil Responsiveness Reflects Rapid Responses to Omalizumab in Chronic Spontaneous Urticaria.
    Oda Y; Fukunaga A; Washio K; Imamura S; Mizuno M; Hatakeyama M; Ogura K; Nishigori C
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1166-1176.e8. PubMed ID: 32898709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
    Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
    Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
    [No Abstract]   [Full Text] [Related]  

  • 5. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
    Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
    J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
    Kaplan AP; Giménez-Arnau AM; Saini SS
    Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.
    MacGlashan D; Saini S; Schroeder JT
    J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab may not inhibit mast cell and basophil activation in vitro.
    Gericke J; Ohanyan T; Church MK; Maurer M; Metz M
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1832-6. PubMed ID: 25257818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relevance of the Basophil High-Affinity IgE Receptor in Chronic Urticaria: Clinical Experience from a Tertiary Care Institution.
    Deza G; March-Rodríguez A; Sánchez S; Ribas-Llauradó C; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM
    J Allergy Clin Immunol Pract; 2019; 7(5):1619-1626.e1. PubMed ID: 30685572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria.
    Alizadeh Aghdam M; Knol EF; van den Elzen M; den Hartog Jager C; van Os-Medendorp H; Knulst AC; Otten HG; Röckmann H
    Clin Exp Allergy; 2020 Mar; 50(3):364-371. PubMed ID: 31925825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basophil FcɛRI expression is linked to time to omalizumab response in chronic spontaneous urticaria.
    Deza G; Bertolín-Colilla M; Sánchez S; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM
    J Allergy Clin Immunol; 2018 Jun; 141(6):2313-2316.e1. PubMed ID: 29518420
    [No Abstract]   [Full Text] [Related]  

  • 12. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
    Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
    Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
    Brás R; Esteves Caldeira L; Bernardino A; Costa C
    Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
    Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
    Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lin
    Ridge K; Moran B; Alvarado-Vazquez PA; Hallgren J; Little MA; Irvine AD; O'Farrelly C; Dunne J; Finlay CM; Conlon N
    Allergy; 2024 Sep; 79(9):2423-2434. PubMed ID: 38634175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In chronic spontaneous urticaria, increased Galectin-9 expression on basophils and eosinophils is linked to high disease activity, endotype-specific markers, and response to omalizumab treatment.
    Ji J; Tang M; Zhao Y; Zhang C; Shen Y; Zhou B; Liu C; Maurer M; Jiao Q
    Allergy; 2024 Sep; 79(9):2435-2447. PubMed ID: 39021347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria.
    Palacios T; Stillman L; Borish L; Lawrence M
    J Allergy Clin Immunol Pract; 2016; 4(3):529-30. PubMed ID: 26725153
    [No Abstract]   [Full Text] [Related]  

  • 18. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
    Metz M; Ohanyan T; Church MK; Maurer M
    J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial D-dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab.
    Asero R
    Clin Exp Dermatol; 2017 Aug; 42(6):667-669. PubMed ID: 28691309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.
    Chang TW; Chen C; Lin CJ; Metz M; Church MK; Maurer M
    J Allergy Clin Immunol; 2015 Feb; 135(2):337-42. PubMed ID: 24948369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.